<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114213">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01781767</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-12-NV-376-CTIL</org_study_id>
    <nct_id>NCT01781767</nct_id>
  </id_info>
  <brief_title>Changes in Metabolic Status in Patients With Total Thyroidectomy</brief_title>
  <acronym>Thyroid cancer</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study objective is to evaluate the change in mitochondrial uncoupling protein 2 (UCP2)
      mRNA expression as function of thyroid activity (TSH, T3 and Free T4).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood will be drown before thyroidectomy, 2 weeks after the operation and 3-4 month after
      the operation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Changes in UCP2 mRNA concentrations.</measure>
    <time_frame>Base line (before opporation), 2 weeks after opporation and for after opporation.</time_frame>
    <safety_issue>No</safety_issue>
    <description>The difference between the result at two weeks and four months compare to base line.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Approximately 4 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting energy expenditure</measure>
    <time_frame>Approximatly 4 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Thyroid Cancer</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood for UCP2 mRNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who were diagnosed with thyroid carcinoma and are going throgh total
        thyroidectomy and recive a thyroid replacement therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who were diagnosed with thyroid carcinoma and are going to have total
             thyroidectomy.

          -  Patients with unbalanced thyroid hormones.

          -  Aged 18-65 years at the time of screening.

          -  Provision of written informed consent.

        Exclusion Criteria:

          -  Patients with Diabetes.

          -  Patients with any other chronic inflammatory diseases.

          -  Steroid treatment.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nachum Vaisman, M.D.</last_name>
    <phone>972-3-6974807</phone>
    <email>vaisman@tasmc.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nachum Vaisman, M.D.</last_name>
      <phone>972-3-6974807</phone>
      <email>vaisman@tasmc.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev. 2001 Jul;81(3):1097-142. Review.</citation>
    <PMID>11427693</PMID>
  </reference>
  <reference>
    <citation>Schwartz HL, Oppenheimer JH. Physiologic and biochemical actions of thyroid hormone. Pharmacol Ther B. 1978;3(3):349-76. Review.</citation>
    <PMID>203955</PMID>
  </reference>
  <reference>
    <citation>Brand MD, Esteves TC. Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. Cell Metab. 2005 Aug;2(2):85-93. Review.</citation>
    <PMID>16098826</PMID>
  </reference>
  <reference>
    <citation>Nicholls DG, Locke RM. Thermogenic mechanisms in brown fat. Physiol Rev. 1984 Jan;64(1):1-64. Review.</citation>
    <PMID>6320232</PMID>
  </reference>
  <reference>
    <citation>Gjedde S, Gormsen LC, Riis AL, Jørgensen JO, Rungby J, Møller N, Weeke J, Pedersen SB. Reduced expression of uncoupling protein 2 in adipose tissue in patients with hypothyroidism. J Clin Endocrinol Metab. 2010 Jul;95(7):3537-41. doi: 10.1210/jc.2009-0907. Epub 2010 Apr 28.</citation>
    <PMID>20427509</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 30, 2013</lastchanged_date>
  <firstreceived_date>January 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>UCP2</keyword>
  <keyword>Thyroid function</keyword>
  <keyword>Thyroid carcinoma</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
